Philip Vutien

Dr. Philip Vutien

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JBJihane N. Benhammou
Jihane N. Benhammou
AMAndrew M. Moon
Andrew M. Moon
JPJoseph R. Pisegna
Joseph R. Pisegna
FSFeng Su
Feng Su
PVPhilip Vutien
Philip Vutien
GIGeorge N. Ioannou
George N. Ioannou

22 June 2023 in Hepatology Communications
Verified
Journal Article
Open access
NKNicole J. Kim
Nicole J. Kim
ACAnne Cravero
Anne Cravero
TVTrang VoPham
Trang VoPham
PVPhilip Vutien
Philip Vutien
RCRotonya Carr
Rotonya Carr
GIGeorge N. Ioannou
George N. Ioannou
HCC, the most common form of primary liver cancer, is the fastest rising cause of cancer-related death in the United States. HCC disproportionately affects racial and ethnic minorities in the United States. A practical framework is needed to organize the complex patient, provider, health system, and societal factors that drive these racial and ethnic disparities. In this narrative review, we adapted and applied the National Institute on Minority Health and Health Disparities (NIMHD) Research Framework to the HCC care continuum, as a step toward better understanding and addressing existing HCC-related disparities. We first summarize the literature on HCC-related disparities by race and ethnicity organized by the framework’s 5 domains (biological, behavioral, physical/built environment, sociocultural environment, and health care system) and 4 levels (individual, interpersonal, community, and societal) of influence. We then offer strategies to guide future research initiatives toward promotion of health equity in HCC care. Clinicians and researchers may help mitigate further inequities and better address racial and ethnic disparities in HCC care by prioritizing the following in HCC research: (1) increasing racial and ethnic minority representation, (2) collecting and reporting HCC-related data by racial and ethnic subgroups, (3) assessing the patient experience of HCC care by race and ethnicity, and (4) evaluating HCC-specific social determinants of health by race and ethnicity. These 4 priorities will help inform the development of future programs and interventions that are tailored to the unique experiences of each racial and ethnic group. Export

20 September 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PVPhilip Vutien
Philip Vutien
NKNicole J. Kim
Nicole J. Kim
AMAndrew M. Moon
Andrew M. Moon
MPMeredith Pearson
Meredith Pearson
FSFeng Su
Feng Su
GIGeorge N. Ioannou
George N. Ioannou

31 July 2021 in Liver Transplantation
Verified
Journal Article
Closed access
PVPhilip Vutien
Philip Vutien
JPJames Perkins
James Perkins
SBScott W. Biggins
Scott W. Biggins
JRJorge Reyes
Jorge Reyes
HIHannah Imlay
Hannah Imlay
ALAjit P. Limaye
Ajit P. Limaye

13 November 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PVPhilip Vutien
Philip Vutien
NKNicole J. Kim
Nicole J. Kim
AMAndrew M. Moon
Andrew M. Moon
KJKay M. Johnson
Kay M. Johnson
KBKristin Berry
Kristin Berry
GIGeorge N. Ioannou
George N. Ioannou

2 December 2024 in Hepatology
Verified
Journal Article
Open access
PVPhilip Vutien
Philip Vutien
AGAbbey Barnard Giustini
Abbey Barnard Giustini
NKNicole J. Kim
Nicole J. Kim
AMAndrew M. Moon
Andrew M. Moon
CHChun-Nan Hsu
Chun-Nan Hsu
GIGeorge N. Ioannou
George N. Ioannou
Background and Aims: Recently proposed “Rule-of-Five” criteria define compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) using liver stiffness (LS) and platelet count. We aimed to validate these criteria by determining whether they are associated with risk of adverse outcomes. Methods and Results: Patients without prior hepatic decompensation or hepatocellular carcinoma (HCC) who underwent LS and platelet measurements (n=17,076), were categorized as follows: no cACLD (LS 2.5-9.9 kPa); probable cACLD (LS 10-14.9 kPa); certain cACLD-no CSPH (LS 15-19.9 kPa and platelets ≥110,000/µL or LS 20-24.9 kPa and platelets ≥150,000/µL); probable CSPH (LS 15-19.9 kPa and platelets <110,000/µL or LS 20-24.9 and platelets <150,000/µL); and certain CSPH (LS ≥25 Kpa), which we further sub-divided into 25-49.9 kPa and 50-75 kPa. During a median follow-up of 2.82 years, each increase in “Rule-of-Five” category was associated linearly with higher risks of death (hazard ratio [HR] 1.22, 95% CI 1.18-1.25) and decompensation (HR 1.52, 95% CI 1.46-1.58). Compared to patients with LS 25-49.9 kPa, those with LS 50-75 kPa (“critical” CSPH) had approximately double the risk of decompensation (11.24 vs. 4.20 per 100 patient-years) and death (9.85 vs. 6.98 per 100 patient-years). Conclusions: The Baveno VII “Rule-of-Five” criteria provide a valid system for stratifying risks of death and hepatic decompensation and should be used routinely in patients with chronic liver disease. Among patients with CSPH (LS ≥25 kPa), the subgroup with LS 50-75 kPa (“critical” CSPH) has approximately double the risk of death and hepatic decompensation than LS 25-49.9 kPa. Export